This site is intended for health professionals only

Takeda to market the CALCICHEW® portfolio in the UK and Ireland


Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE


Takeda UK Limited has announced that it is now the sole holder of the Marketing Authorisation for the CALCICHEW® portfolio in UK and Ireland following a transfer from Shire Pharmaceuticals Ireland Limited.
Takeda will be responsible for the promotion, marketing, sales and distribution of the CALCICHEW® portfolio in both countries.  The financial arrangements related to this agreement have not been disclosed and remain confidential between Takeda and Shire.
“The transfer of Marketing Authorisation for the CALCICHEW® portfolio is a great development for Takeda and it will add significant financial revenues to Takeda in the UK and Ireland and there is significant potential for growth in both countries” said Yasuhiro Fukutomi, Managing Director, Takeda UK and Cluster Lead for UK & Ireland.  He continues “we are also very pleased to be able to continue to work in the area of osteoporosis, offering patients and physicians treatment choice and support to help with the management of this disease”.
The CALCICHEW D3 portfolio is indicated for the prevention and treatment of vitamin D/calcium deficiency and for the supplementation of vitamin D and calcium as an adjunct to specific therapy for osteoporosis, in pregnancy, in established vitamin D dependent osteomalacia and in other situations requiring therapeutic supplementation of malnutrition.(1) It consists of a number of products containing calcium, with or without vitamin D3.  The major patient group, which is prescribed calcium and/or vitamin D3, is the elderly (especially women) who are at risk of or have diagnosed osteoporosis and/or have an increased risk of falls.
The supply and distribution of CALCICHEW® products will not be affected by the marketing authorisation transfer. CALCICHEW® products can be ordered as before using PIP/EAN codes as these will not be affected by the transfer. Questions relating to the supply of the CALCICHEW® portfolio can be directed to Takeda UK Medical Information on [email protected] / 01628 537 900.
  1. CALCICHEW D3 Forte Tablets. Summary of product characteristics (SmPC). Available at Last accessed November 2013

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine